In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage.
Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Lung Cancer Care and Research Not Immune to Socioeconomic, Ethnic, Racial, and Gender-related .
International Association for the Study of Lung CancerJanuary 29, 2021 GMT
SINGAPORE, Jan. 28, 2021 (GLOBE NEWSWIRE) Several leading international lung cancer researchers at a press today presented compelling new data revealing that factors of race, gender, sexual orientation and income continue to be significant barriers to those living with lung cancer. The press briefing is part of the IASLC’s World Conference on Lung Cancer 2020 Singapore.
(Note: you may access a recording of the press briefing at this link: https://vimeo.com/505823998/d5260e13a9 )
International Association for
Lung Cancer Care and Research Not Immune to Socioeconomic, Ethnic, Racial, and Gender-related Factors that Create Disparities
Lung Cancer Care and Research Not Immune to Socioeconomic, Ethnic, Racial, and Gender-related Factors that Create Disparities
Press Briefing at IASLC World Conference on Lung Cancer 2020 Singapore
SINGAPORE, Jan. 28, 2021 (GLOBE NEWSWIRE) Several leading international lung cancer researchers at a press today presented compelling new data revealing that factors of race, gender, sexual orientation and income continue to be significant barriers to those living with lung cancer. The press briefing is part of the IASLC’s World Conference on Lung Cancer 2020 Singapore.
E-Mail
(Singapore January 28, 2021 11:00 p.m. SPT/10:00 a.m. EST) Several leading international lung cancer researchers at a press briefing held by the International Association for the Study of Lung Cancer today, presented compelling new data revealing that factors of race, gender, sexual orientation and income continue to be significant barriers to those living with lung cancer. The press briefing is part of the IASLC s World Conference on Lung Cancer 2020 Singapore.
The press briefing is moderated by IASLC Communications Committee Chair Dr. Anne-Marie Baird, senior research fellow at Trinity College in Dublin and president of Lung Cancer Europe (LuCE), a nonprofit that aims to provide a voice for people impacted by lung cancer in Europe. Patient Research Advocate Jill Feldman, co-founder of the patient advocacy group, The EGFR Resisters, will contribute insights from the advocacy community s perspective.